Reviewed by Michael Gill, B. Sc.
25 Gastric Adenocarcinoma Clinical Trials Near Me
Top Hospitals for Gastric Adenocarcinoma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
5Active Trials
98All Time Trials for Gastric Adenocarcinoma
2005First Gastric Adenocarcinoma Trial
Image of Dana-Farber Cancer Institute in Massachusetts.
Dana-Farber Cancer Institute
Boston
4Active Trials
57All Time Trials for Gastric Adenocarcinoma
1998First Gastric Adenocarcinoma Trial
Top Cities for Gastric Adenocarcinoma Clinical Trials
Most Recent Gastric Adenocarcinoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
1/13/2022
Phase 1 & 2
Top Treatments for Gastric Adenocarcinoma Clinical Trials
Treatment Name
Active Gastric Adenocarcinoma Clinical Trials
All Time Trials for Gastric Adenocarcinoma
First Recorded Gastric Adenocarcinoma Trial
Paclitaxel
2
104
1998
Methadone
1
1
2022
Pembrolizumab
1
73
2014
BLU-451
1
1
2022
BLU-701
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Gastric Adenocarcinoma
Treatment
Year
Sponsor
EndoTAG-1
2018
SynCore Biotechnology Co., Ltd.
oleclumab
2018
MedImmune LLC
Paclitaxel protein-bound
2017
HonorHealth Research Institute
3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
2017
University of Texas Southwestern Medical Center
APX005M
2017
Parker Institute for Cancer Immunotherapy
Gallium Ga 68-labeled PSMA-11
2017
Andrei Iagaru
Paclitaxel
2017
M.D. Anderson Cancer Center

What Are Gastric Adenocarcinoma Clinical Trials?

Gastric adenocarcinoma refers to stomach cancer, which results from the uncontrolled growth of gland cells in the innermost lining of the stomach. Adenocarcinomas makeup up almost 95% of all gastric cancer and can exist in either the intestinal type or the diffuse type, where the latter is harder to treat and spreads faster.

Gastric Adenocarcinoma can cause various symptoms, including loss of appetite, fatigue, weight loss, nausea, blood in vomit, and stomach pain. If the cancer metastasizes, it becomes difficult to treat and might prove fatal.

Gastric Adenocarcinoma clinical trials are research studies that aim to improve current treatment methods and obtain information on disease etiology and patient response. When clinical trials show that a new treatment is better than the standard, it may replace the latter.

Why is Gastric Adenocarcinoma Being Studied Through Clinical Trials?

In the United States, about 26,000 new reports of stomach cancer are made yearly. 95% of these cancers are caused by gastric adenocarcinoma. Moreover, scientists are still unsure about the exact cause of cancer. However, many factors may contribute to the development.

While at an early stage, if cancer exists as a tumor, it can be treated effectively, with a five-year survival rate of 70%. However, if cancer spreads, it becomes difficult to treat, and the five-year survival rate falls to 32%.

Additionally, current treatment methods show many adverse side effects, and some are not applicable in late-stage diagnosis. Moreover, these treatment methods are costly and often put a strain on the already weakened body.

Gastric Adenocarcinoma clinical trials aim to find new and improved treatment methods to prevent the spread of cancer, allow early diagnosis, and gain information on its progression.

What Are The Types of Treatment Available For Gastric Adenocarcinoma?

Current treatment methods for Gastric Adenocarcinoma include:

  • Surgery: Surgical methods include removing and resecting the tumor from the tissue. The surgery may include a subtotal gastrectomy or total gastrectomy.
  • Endoscopic Mucosal Resection: An endoscope is used to remove precancerous growth from the stomach lining.
  • Chemotherapy: a combination of chemicals is administered orally or through an injection in the vein to target and kill cancer cells.
  • Radiation Therapy: using high energy X-ray radiation to inhibit the growth of or kill cancer cells.
  • Targeted Therapy: The use of monoclonal antibody drugs such as trastuzumab and ramucirumab for targeted cancer cell killing. Also, involve the use of kinase inhibitors such as regorafenib to prevent the growth of cancer cells.
  • Immunotherapy: Using methods to boost or restore the body’s immune system against cancer cells.

What Are Some Recent Breakthrough Clinical Trials for Gastric Adenocarcinoma?

Some of the recent breakthrough gastric adenocarcinoma clinical trials include:

2022: a clinical trial (NCT02335411) by Merch Sharp & Dohme to assess the safety of pembrolizumab, alone and in combination with cisplatin and 5-fluorouracil, in recurrent gastric adenocarcinoma patients. The number of participants experiencing adverse events was measured.

2021: a clinical trial (NCT05052801) by Amgen to study the efficacy of pertuzumab in combination with oxaliplatin, 5-fluorouracil, and leucovorin to treat gastric cancer and measure overall survival rate in patients with a mutation in the Fibroblast Growth Receptor 2b.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. Review. https://pubmed.ncbi.nlm.nih.gov/356230692 Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. https://pubmed.ncbi.nlm.nih.gov/356230693 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(⋅-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666794 Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942. https://pubmed.ncbi.nlm.nih.gov/256260355 Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. https://pubmed.ncbi.nlm.nih.gov/307149876 Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020 Mar 5;382(10):917-928. doi: 10.1056/NEJMoa1910038. https://pubmed.ncbi.nlm.nih.gov/321308147 Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013 Nov;64(5):713-719. doi: 10.1016/j.eururo.2013.05.059. Epub 2013 Jun 12. https://pubmed.ncbi.nlm.nih.gov/237873578 Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003 Fall;8(3):149-54. https://pubmed.ncbi.nlm.nih.gov/146579829 Krücker J, Xu S, Glossop N, Viswanathan A, Borgert J, Schulz H, Wood BJ. Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J Vasc Interv Radiol. 2007 Sep;18(9):1141-50. https://pubmed.ncbi.nlm.nih.gov/1780477710 Doskey CM, Buranasudja V, Wagner BA, Wilkes JG, Du J, Cullen JJ, Buettner GR. Tumor cells have decreased ability to metabolize H(2)O(2): Implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016 Dec;10:274-284. doi: 10.1016/j.redox.2016.10.010. Epub 2016 Oct 28. https://pubmed.ncbi.nlm.nih.gov/27833040